Core Viewpoint - The National Development and Reform Commission has officially issued the "Implementation Plan for Accelerating Green Transformation Development in the Chang-Zhu-Tan Ecological Green Heart," aiming to explore new models for green transformation and establish an ecological safety barrier in highly urbanized areas [1][2]. Group 1: Ecological and Environmental Initiatives - The plan emphasizes the integration of ecology and safety, focusing on enhancing air quality, water management, and solid waste treatment to improve the ecological environment of the green heart [1]. - Major ecological projects will be implemented, including soil erosion control, abandoned mine restoration, and forest quality improvement, to enhance biodiversity and ecological quality [1][2]. - The establishment of an ecological safety framework will be prioritized, with a focus on ecological corridor management and resilient city construction to strengthen safety resilience [1]. Group 2: Industrial and Economic Development - The plan aims to strengthen industrial support for the green heart by developing ecological agriculture, forestry, and tourism, promoting deep integration with culture, tourism, health, and sports [2]. - It encourages the green transformation of industries, including the establishment of technology innovation platforms in the ecological sector and the exit of outdated high-energy and high-emission capacities [2]. - Future industry clusters will be cultivated, focusing on life sciences, biomanufacturing, and health industries, as well as expanding applications in home and industrial robotics [2]. Group 3: Quality of Life and Community Development - The plan promotes the improvement of green infrastructure, including the construction of a 1,000-kilometer cycling and walking path network [2]. - It supports urban-rural green development, advocating for green building practices and the construction of beautiful rural areas [2]. - The promotion of a green lifestyle will be emphasized, leveraging high-quality ecological resources for ecological civilization education [2].

2025年第九届21世纪大健康产业竞争力研究"阳光"案例荣誉榜正式揭晓，澳新生命科技领军企业 EZZLifeScienceHoldingsLimited凭借在基因研发领域的突破性成果与高效市场转化能力，成功斩获"创新 研发卓越类-[阳光」年度杰出研发创新企业"殊荣！这一权威认可，不仅彰显了EZZ以基因技术为核心的 科研方向的行业领先性，更印证了其在全生命周期健康管理领域的深厚积淀与创新实力，成为大健康产 业精准化转型的标杆典范。 基因研发筑壁垒 技术攻坚锚定长期健康布局 在"健康中国2030"规划纲要的指导下，EZZ致力于将全球科研资源与中国本土市场需求有机结合，作为 其研发创新的重要路径。2025年，EZZ与悉尼大学达成重磅战略合作，围绕成长系列产品开展系统科学 的功效验证——这是成长型营养补充品首次进入世界顶级高校的科研体系，标志着该品类从"概念驱 动"正式迈向"实证驱动"，为行业树立了科学研发的新标杆。 针对中国市场，EZZ秉持"全球科研支撑，服务本土健康"的核心理念，进行全方位本土化适配。结合中 国儿童主食摄入多、糖分易超标等饮食特点，严格控制产品糖分与热量，让家长更放心；考虑到儿童吞 咽习惯与口感偏 ...

2025年第九届21世纪大健康产业竞争力研究"阳光"案例荣誉榜正式揭晓，澳新生命科技领军企业 EZZLifeScienceHoldingsLimited凭借在基因研发领域的突破性成果与高效市场转化能力，成功斩 获"创新研发卓越类-[阳光」年度杰出研发创新企业"殊荣！这一权威认可，不仅彰显了EZZ以基因技 术为核心的科研方向的行业领先性，更印证了其在全生命周期健康管理领域的深厚积淀与创新实力， 成为大健康产业精准化转型的标杆典范。 在大健康产业从"广谱健康"迈向"精准健康"的关键转型期，EZZ跳出传统制药企业单一病 症 聚 焦 的 研 发 框 架 ， 以 " 以 基 因 为 中 心 的 生 命 科 学 " 为 核 心 战 略 ， 直 击 健 康 管 理 的 底 层 逻 辑。不同于传统研发仅停留在表面需求满足，EZZ深入细胞与基因层面，探索健康维持与 发展的本质规律，彻底打破了传统模式在健康支持深度上的局限，为用户提供更具科学性 的健康解决方案。 为 夯 实 科 研 根 基 ， EZZ 倾 力 打 造 了 覆 盖 全 球 的 顶 尖 研 发 网 络 —— 携 手 新 西 兰 基 因 研 究 中 心、奥克兰大学、悉 ...

Group 1 - The core message of the speech emphasizes a shift in health investment from treating existing diseases to preventing them, thereby extending healthy lifespans [1][3] - The chairman of Huaxi Bio, Zhao Yan, predicts that chronic diseases such as cancer, diabetes, hypertension, hyperlipidemia, hyperglycemia, and even Alzheimer's may be curable in the next decade, contingent on the importance placed on prevention [1] - The speech aligns with the "Healthy China 2030" initiative, which advocates for a preventive approach to health, promoting healthy lifestyles and early diagnosis and treatment to reduce disease occurrence [3] Group 2 - Zhao Yan highlights that the essence of aging intervention is not merely anti-aging but rather controlling risks to reduce the incidence of chronic diseases [3] - The proposed path to health should focus on preventing diseases, minimizing their occurrence, and delaying their onset, with technological innovation playing a crucial role in this intervention [3]

在慢病管理上，尹烨给出了简单易行的健康建议：控制体重与血压、多茶少酒、多醋少盐、多水少油、 多动少坐，即使久坐也可通过捏手、抖腿等方式缓解压力。他特别强调，健康管理应从日常细节入手， 比如每天减少1克盐摄入、饭后散步5分钟稳定血糖，这些微小改变能有效降低慢病风险。 对于认知障碍等难题，尹烨分享了前沿研究成果：接种减毒型带状疱疹疫苗可降低20%的认知障碍发生 率，建议40岁以上人群尽早接种；健康大脑需要远离什么？"超加工食品，不要没事熬夜，不要刷垃圾 短视频，希望大家戒烟限酒，避免争强好胜，远离负面情绪，远离恶劣环境，切勿作恶越来越多的事情 告诉我们年轻时候行的善会滋养你，做的恶随着年龄增长了会形成重要的心霾，勿以恶小而为之，勿以 善小而不为。"他说。 专题：财经年会2026：预测与战略暨2025全球财富管理论坛 《财经》年会2026：预测与战略暨2025全球财富管理论坛于2025年12月18-20日在北京举行。华大集团 首席执行官尹烨指出，从人类寿命演进来看，科技进步带来的改变尤为显著。1800年全球人均预期寿命 不足30岁，1949年中国仅为39岁，而如今全球人均寿命已达73岁，中国更是提升至79岁。尹烨表 ...

港投公司在报告中强调其"资本带动"效应。截至2025年6月30日，公司每投资1港元，可带动超过6港元的市场长期资金跟投。成立两年间，投资组合中已有2 家企业成功在港上市，另有10余家企业已于2025年内提交或计划提交上市申请，其中5家在上市前已成为独角兽企业。 这些被投企业为香港本地经济带来实质贡献：累计租赁楼面面积超过26.8万平方米，创造直接职位超过6,400个，注册知识产权达109项，并举办行业活动164 场。 构建生态圈，强化香港"超级联系人"角色 港投公司积极搭建涵盖"政、产、学、研、投"的生态圈，已与香港城市大学、中文大学、科技大学、理工大学及香港大学开展超过100项协作项目。此外， 通过设立海外合作基地、举办国际峰会等形式，助力香港巩固其"超级联系人"与"超级增值人"的双重角色。 港投公司行政总裁陈家齐表示：港投公司是坚持长期投资、价值投资、责任投资的专业机构投资者。我们秉持全球视野，加强在区域和国际市场上发挥影响 力，贡献国家发展，说好香港故事，助力构筑互利共赢的市场规则和投资格局。同时，我们透过构建港投公司生态圈，汇聚本地及海外公私营界别的资源和 智慧，助力转型、重塑、定义香港产业、经济和金 ...

Core Insights - The 2025 VENTURE50 results were announced, highlighting key companies in the sectors of AI, hard technology, and life sciences, with a focus on high-growth enterprises [2][26] - AI companies dominated the selection, accounting for 49% of the total, with a shift from technology validation to commercial implementation driven by policy support and market demand [2] Group 1: Company Categories - The "Fengyun 50" category includes companies that have completed Series B funding or were established before 2022, while the "Xinya 50" category includes those in Series B or earlier and established after 2022 [2] - The selected companies in the AI sector are focusing on embodied intelligence, generative AI, and "AI + vertical scenarios," indicating a trend towards practical applications [2] Group 2: Geographic Distribution - The majority of selected companies are located in first-tier cities such as Shanghai, Beijing, and Shenzhen, which account for 72% of the total, showcasing the concentration of innovation resources and talent [3] - Emerging first-tier cities like Suzhou and Hangzhou are becoming significant innovation hubs, while core cities in central and western China are also seeing notable entries, reflecting a nationwide effort to enhance the quality of the industrial ecosystem [3] Group 3: Selected Companies - Notable companies in the 2025 VENTURE50 include: - Beidou Zhili (BICV) focusing on automotive intelligence and navigation - Megatech specializing in AI and automation technologies - Tianbing Technology, a private liquid rocket developer - Yuyuan Technology, a provider of intelligent robots [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Group 4: Investment and Growth Metrics - Since its inception in 2006, VENTURE50 has seen over 81,000 companies participate, with cumulative follow-up financing exceeding 351.76 billion RMB, and a follow-up financing rate of 34.64% in the last three years [26] - The initiative aims to connect thousands of tech innovation companies with hundreds of leading investment institutions, facilitating the growth of startups into unicorns and promoting deep integration between industry and capital [26]

Core Insights - The Hong Kong Investment Company has officially released its first annual report for 2024, marking a significant milestone since its establishment [1] Financial Performance - As of December 31, 2024, the total asset size of the company is HKD 64.007 billion, with less than 20% of the initial capital invested in projects [1] - The company achieved investment income of HKD 2.345 billion and recorded an operating profit of HKD 2.252 billion [1] Investment Allocation - The investment allocation in the hard technology sector is notably high at 71%, while investments in life sciences and new energy/green technology account for 13% and 11% respectively [1]

Core Insights - The Hong Kong Investment Company has officially released its first annual report for 2024, marking a significant milestone since its establishment [1] Financial Performance - As of December 31, 2024, the total asset size of the company is HKD 64.007 billion, with invested project funds accounting for less than one-fifth of the initial capital [1] - The company achieved investment income of HKD 2.345 billion and recorded an operating profit of HKD 2.252 billion [1] Investment Allocation - The investment allocation shows a high concentration in the hard technology sector, which accounts for 71% of the total investments [1] - Investments in life sciences and new energy/green technology represent 13% and 11% respectively [1]

Group 1 - The company, 信铭生命科技 (00474), reported a revenue of HKD 29 million for the six months ending September 30, 2025, representing a year-on-year increase of 26.09% [1] - The profit attributable to the company's owners was HKD 386 million, marking a turnaround from a loss to profit year-on-year [1] - The basic earnings per share were HKD 0.0527 [1]